Retinal Degeneration - Pipeline Insight, 2018 - Analysis of 150 Products and 120 Companies - ResearchAndMarkets.com

DUBLIN--()--The "Retinal Degeneration - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

"Retinal Degeneration- Pipeline Insight, 2018" report outlays comprehensive Insight of present scenario and growth prospects across Retinal Degeneration. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 150+ products along with 120+ companies involved.

Products covered by Phase

  • Phase III, Phase II and Phase I
  • Pre-clinical and Discovery
  • Inactive (Dormant and Discontinued)

Overview of pipeline development activities for Retinal Degeneration

Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.

Therapeutic segmentation of products for Retinal Degeneration

The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this indication.

Companies Mentioned: Sample List

  • Aciont
  • Acucela
  • Adalta
  • Adverum Biotechnologies
  • Altacor
  • Amarantus
  • CoMentis
  • Daiichi Sankyo
  • Gyroscope Therapeutics
  • Healios
  • Hemera Biosciences
  • Horama
  • Iconic Therapeutics
  • ID Pharma
  • Inflectis Bioscience
  • Ionis Pharmaceuticals
  • Janssen
  • Neurotech Pharmaceuticals
  • NightstaRx
  • Novartis
  • OliX Pharmaceuticals
  • Omeros
  • Ophthotech
  • Ophthotech Corporation
  • OPKO Health
  • Opsis Therapeutics
  • Opthea
  • Opthotech Corporation
  • Orphagen Pharmaceuticals
  • ProRetina
  • Stealth BioTherapeutics
  • Synthetic Biologics
  • ThromboGenics
  • Tyrogenex
  • Vision Medicines

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/fg4cls/retinal?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Optical Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Optical Disorders Drugs